novel.JPG

22 NOVEL DRUGS

Innovative products that serve unmet medical needs/significantly advance patient care. Have chemical structures that have never been approved before.

Adlyxin,  Anthim,  Axumin,  Briviact,  Cinqair, Defitelio, Epclusa, Eucrisa, Exondys 51, Lartruvo, Netspot, Nuplazid, Ocaliva, Rubraca, Spinraza, Taltz, Tecentriq, Venclexta, Xiidra, Zepatier, Zinbryta, Zinplava

SUMMARY

  • Impact: Public health, First-in-class,  Rare diseases
  • Innovation: Breakthrough, Fast Track, Pirority Review, Accelerated Approva
  • Predictability: Met PDUFA goal date
  • Access: First cycle approval, First approval in US

LEARN

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s